Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 16/20 | 1.00 |
| ▸ | PTGER1 | P34995 | 2/20 | 1.00 |
| ▸ | PTGFR | P43088 | 1/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 1/20 | 1.00 |
| ▸ | PTGER2 | P43116 | 1/20 | 1.00 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.59 |
| ▸ | PDE2A | O00408 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5772139 | 0.95 | TBXA2R (1.00) | TBXA2RPTGER1PTGFRPTGER3PTGER2 | |
| SCHEMBL14621525 | 0.90 | TBXA2R (0.81) | TBXA2RPTGER1PTGFRPTGER3PTGER2 | |
| SCHEMBL5777754 | 0.87 | TBXA2R (0.85) | TBXA2RPTGER1PTGFRPTGER3PTGER2 | |
| SCHEMBL10312763 | 0.85 | TBXA2R (0.74) | TBXA2RPTGER1PTGFRPTGER3PTGER2 | |
| SCHEMBL6690976 | 0.84 | TBXA2R (0.90) | TBXA2RPTGER1PTGFRPTGER3PTGER2 | |
| SCHEMBL6731280 | 0.84 | TBXA2R (0.81) | TBXA2RPTGER1PTGFRPTGER3PTGER2 | |
| SCHEMBL5774875 | 0.81 | TBXA2R (0.75) | TBXA2RPTGER1PTGFRPTGER3PTGER2 | |
| SCHEMBL5775922 | 0.80 | TBXA2R (1.00) | TBXA2RPTGER1PTGFRPTGER3PTGER2 | |
| SCHEMBL990995 | 0.80 | TBXA2R (0.73) | TBXA2RPTGER1PTGFRPTGER3PTGER2 | |
| SCHEMBL5800203 | 0.79 | TBXA2R (1.00) | TBXA2RPTGDRPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9889082-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160346186-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER, AND BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-12-01 | — | — | US | disclosed |
| US-9254293-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-02-09 | — | — | US | disclosed |
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20110118292-A1 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS | CHENG KANG | 2011-05-19 | — | — | US | disclosed |
| US-20110118292-A1 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS | CHENG KANG | 2011-05-19 | — | — | US | disclosed |
| EP-1901731-B1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2011-03-02 | — | — | EP | disclosed |
| EP-2286816-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | MERCK SHARP & DOHME (I.A.) CORP. (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20070299122-A1 | Method of Treating Pathological Blushing | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| US-20070299122-A1 | Method of Treating Pathological Blushing | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20070244107-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions | MERCK & CO., INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070244107-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions | MERCK & CO., INC. | 2007-10-18 | — | — | US | disclosed |
| US-7241792-B2 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241792-B2 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346186-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER, AND BPH | AR, BPHL, PTGS2 | TBXA2R 888/4885PTGER1 29/4885PTGFR 12/4885 |
| US-20070299122-A1 | Method of Treating Pathological Blushing | BDKRB2, BDKRB1, PTGIR | TBXA2R 9/4885PTGER1 15/4885PTGFR 109/4885 |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | GPR119, FFAR1, HCAR1 | TBXA2R 53/4885PTGER1 258/4885PTGFR 932/4885 |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ACE, ACE2, AGTR2 | TBXA2R 434/4885PTGER1 258/4885PTGFR 343/4885 |
| US-20070244107-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions | LDLR, LIPA, APOB | TBXA2R 68/4885PTGER1 81/4885PTGFR 125/4885 |
| US-20110118292-A1 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS | LDLR, HCAR1, FFAR1 | TBXA2R 37/4885PTGER1 300/4885PTGFR 605/4885 |
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | TBXA2R 56/4885PTGER1 171/4885PTGFR 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.